Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39692006.
- Also identified by DOI 10.1161/CIRCRESAHA.124.325562 and PMC identifier 11747791.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When human induced pluripotent stem cells (hiPSCs) that CCND2-OE (overexpressed cyclin-D2) were differentiated into cardiomyocytes (<sup>CCND2-OE</sup>hiPSC-CMs) and administered to the infarcted hearts of immunodeficient mice, the cells proliferated after administration and repopulated >50% of the scar. Here, we knocked out human leukocyte antigen class I and class II expression in <sup>CCND2-OE</sup>hiPSC-CMs (<sup>KO/OE</sup>hiPSC-CMs) to reduce the cells' immunogenicity and then assessed the therapeutic efficacy of <sup>KO/OE</sup>hiPSC-CMs for the treatment of myocardial infarction. <sup>KO/OE</sup>hiPSC-CM and wild-type hiPSC-CM (<sup>WT</sup>hiPSC-CM) spheroids were differentiated in shaking flasks, purified, characterized, and intramyocardially injected into pigs after ischemia/reperfusion injury; control animals were injected with basal medium. Cardiac function was evaluated via cardiac magnetic resonance imaging, and cardiomyocyte proliferation was assessed via immunostaining and single-nucleus RNA sequencing. Measurements of cardiac function and scar size were significantly better in pigs treated with <sup>KO/OE</sup>hiPSC-CM spheroids than in animals treated with medium or <sup>WT</sup>hiPSC-CM spheroids. <sup>KO/OE</sup>hiPSC-CMs were detected for just 1 week after administration, but assessments of cell cycle activity and proliferation were significantly higher in the endogenous pig cardiomyocytes of the hearts from the <sup>KO/OE</sup>hiPSC-CM spheroid group than in those from the other 2 groups. Single-nucleus RNA-sequencing analysis identified a cluster of proliferating cardiomyocytes that was significantly more prevalent in the <sup>KO/OE</sup>hiPSC-CM spheroid-treated hearts (3.65%) than in the hearts from the medium (0.89%) or <sup>WT</sup>hiPSC-CM spheroid (1.33%) groups at week 1. YAP (Yes-associated protein) protein levels and nuclear localization were also significantly upregulated in pig cardiomyocytes after treatment with <sup>KO/OE</sup>hiPSC-CM spheroids. Follistatin, which interacts with the HIPPO/YAP pathway, was significantly more abundant in the medium from <sup>KO/OE</sup>hiPSC-CM spheroids than <sup>WT</sup>hiPSC-CM spheroids (30.29±2.39 versus 16.62±0.83 ng/mL, <i>P</i>=0.0056). Treatment with follistatin increased <sup>WT</sup>hiPSC-CM cell counts by 28.3% over 16 days in culture and promoted cardiomyocyte proliferation in the infarcted hearts of adult mice. <sup>KO/OE</sup>hiPSC-CM spheroids significantly improved cardiac function and reduced infarct size in pig hearts after ischemia/reperfusion injury by secreting follistatin, which upregulated HIPPO/YAP signaling and proliferation in endogenous pig cardiomyocytes.
Medical subject headings
- Myocytes, Cardiac
- Cell Proliferation
- Myocardial Infarction
- Ventricular Remodeling
- Induced Pluripotent Stem Cells
- Follistatin